GlassScriptPhysician profile
Jeffrey M Legrett
NPI 1548240278
$2,864.61
in general payments reported to CMS, 2019-2025
34 companies · $587 in 2025
The $587 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $128 · 2021: $112 · 2022: $214 · 2023: $880 · 2024: $606 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $346.72 | 2019-2025 | |
| Lilly USA, LLC | $285.92 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $258.88 | 2019-2024 | Veozah |
| Novo Nordisk INC | $213.19 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $190.23 | 2022-2025 | |
| Baxter Healthcare | $187.96 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $145.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.26 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $111.14 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.69 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $92.74 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $82.01 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $76.32 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $68.17 | 2023-2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $66.23 | 2023-2024 | Xarelto |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $53.85 | 2019-2023 | Afrezza |
| Phathom Pharmaceuticals, INC. | $48.67 | 2023-2025 | Voquezna |
| Amgen INC. | $48.58 | 2020-2024 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $43.44 | 2025 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $40.87 | 2022 | |
| Inogen, INC. | $34.96 | 2022-2024 | |
| Amarin Pharma, INC. | $30.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.74 | 2019 | |
| Inspire Medical Systems, INC. | $21.56 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.23 | 2023 | |
| Alkermes, INC. | $21.04 | 2023 | Vivitrol |
| Sumitomo Pharma America, INC. | $18.60 | 2025 | Gemtesa |
| Scilex Pharmaceuticals INC. | $16.87 | 2019 | |
| Lundbeck LLC | $16.39 | 2025 | Rexulti |
| Almatica Pharma LLC | $15.98 | 2025 | Teriparatide |
| Alnylam Pharmaceuticals INC. | $15.12 | 2023 | Givlaari |
| Sanofi-Aventis U.S. LLC | $14.79 | 2020 | |
| Medtronic, INC. | $14.67 | 2023 | Clydesdale Ptc Spinal System |
| Azurity Pharmaceuticals, INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Legrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.